Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Rexahn Pharmaceuticals logo — TARGETING DIFFICULT TO TREAT CANCERS

Rexahn Pharmaceuticals

TARGETING DIFFICULT TO TREAT CANCERS

Founded 2001 United States Rockville, United States 7 employees Post-IPO Equity Total: $13.60M Biotechnology, Medical Devices +1

General Information

Company Name Rexahn Pharmaceuticals
Founded Year 2001
Location United States Rockville, United States
Founders / Decision Makers
Team member
Employees 7
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Rexahn Pharmaceuticals. To contact Rexahn Pharmaceuticals, visit rexahn.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Rexahn Pharmaceuticals compare?

A PDF of Rexahn Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Rexahn Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals is a NY Stock Exchange listed biopharmaceutical company focusing on the development of targeted therapeutics for cancer treatment. Established in 2001, Rexahn's mission is to enhance the lives of cancer patients by creating next-generation therapies with increased efficacy and reduced side effects. Its products specifically target proteins implicated in cancer cell proliferation, indicating potential effectiveness against drug-resistant and difficult-to-treat cancers. Currently, the company has two product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and others in preclinical development, including RX-0201.

During its last investment round on 23 January 2019, the company secured an $8.60M Post-IPO Equity investment, demonstrating confidence from investors in its research and development initiatives. Rexahn's focus on addressing unmet medical needs in cancer treatment positions it as a promising player in the biotechnology and pharmaceutical industries. For further details on the company and its oncology programs, individuals can visit www.rexahn.com.

Business keywords: Rexahn Pharmaceuticals Inc., biopharmaceutical, cancer, clinical stage, therapeutics, targeted therapy, cancer treatment, oncology, product candidates, Phase 2 clinical development, drug resistance, toxicity, side effects, FDA-approved, preclinical development

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $8.60M -
23 Jan 2019
Post IPO Equity $5.00M -
11 Oct 2013

Rexahn Pharmaceuticals Alternatives & Competitors

View All Alternatives
Rexahn Pharmaceuticals vs
ORIC Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc. United States

Overcoming Resistance In Cancer

Post-IPO Equity
119 employees
Biopharma, Biotechnology
Rexahn Pharmaceuticals vs
Prelude Therapeutics
Prelude Therapeutics United States

Precision Oncology, Redefined.

Post-IPO Equity
126 employees
Biopharma, Biotechnology
Rexahn Pharmaceuticals vs
Onena Medicines
Onena Medicines Switzerland

AI-centric preclinical company discovering and developing novel biopharmaceuticals to treat cancer a...

9 employees
Biotechnology, Health Care
Also compare with: Rexahn Pharmaceuticals vs CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc. View all alternatives

FAQ About Rexahn Pharmaceuticals

TARGETING DIFFICULT TO TREAT CANCERS
Rexahn Pharmaceuticals was founded in 2001.
Rexahn Pharmaceuticals is headquartered in Rockville, United States.
Rexahn Pharmaceuticals operates in Biotechnology, Medical Devices and Pharmaceutical. Its work centres on Rexahn Pharmaceuticals Inc., biopharmaceutical, cancer and clinical stage.
Rexahn Pharmaceuticals has approximately 7 employees.
Rexahn Pharmaceuticals has completed 2 funding rounds, raising a total of $13.60M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Rexahn Pharmaceuticals include ORIC Pharmaceuticals Inc., Prelude Therapeutics, Onena Medicines, Genprex, Inc., CASI Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Rexahn Pharmaceuticals and ORIC Pharmaceuticals Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Rexahn Pharmaceuticals, https://bouncewatch.com/company/rexahn-pharmaceuticals, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout